President Trump Orders FDA to Fast-Track Psychedelic Treatments for Mental Health and Veterans

People with serious mental illnesses like major depression and substance abuse disorder who haven't responded to standard treatments could gain access to psychedelic therapies through the Right to Try pathway and accelerated FDA approvals. This opens up new treatment options for a population that has had limited alternatives, though actual availability depends on clinical trial results and rescheduling timelines.

Veterans are specifically prioritized in this order due to their disproportionately high suicide rate. The VA is directed to collaborate with HHS and the FDA on clinical trials and data sharing for psychedelic treatments, which could expand treatment options for veterans with treatment-resistant PTSD, depression, and substance abuse. With over 6,000 veteran suicides per year, even modest improvements in treatment could save many lives.

The VA system is directed to expand its involvement in psychedelic drug research and clinical trials, which could eventually add new treatment options to the VA healthcare system. Veterans who receive care through the VA may gain earlier access to these therapies than the general population, given the VA's direct role in data sharing and trial participation.

People with chronic substance abuse disorders are among the specific populations targeted by this order. Ibogaine and other psychedelic compounds have shown promise in treating addiction in clinical studies. If these treatments gain FDA approval and are rescheduled, they could provide new options for patients who have cycled through traditional addiction treatments without lasting recovery.